Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | PTPRF | P10586 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | WHR1 | P49842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21709479 | 0.94 | KMT2A (0.37) | MEN1KMT2AATMPDK1 | |
| SCHEMBL21709427 | 0.93 | MEN1 (0.36) | MEN1KMT2AATMPDK1WHR1 | |
| SCHEMBL21709332 | 0.93 | KMT2A (0.38) | MEN1KMT2AATMPDK1WHR1 | |
| SCHEMBL21709472 | 0.91 | MEN1 (0.32) | MEN1KMT2AATM | |
| SCHEMBL21709333 | 0.89 | MEN1 (0.34) | MEN1KMT2AATMPDK1WHR1 | |
| SCHEMBL21709325 | 0.89 | MEN1 (0.34) | MEN1KMT2AATMPDK1WHR1 | |
| SCHEMBL21709383 | 0.89 | MEN1 (0.38) | MEN1KMT2AATMPDK1WHR1 | |
| SCHEMBL21709311 | 0.89 | MEN1 (0.35) | MEN1KMT2AATMPDK1WHR1 | |
| SCHEMBL21709314 | 0.89 | KMT2A (0.37) | MEN1KMT2AATMPDK1 | |
| SCHEMBL24969264 | 0.88 | PTPRF (0.33) | PTPRFPTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048207-A1 | COMPOUNDS WITH ARYLAMINE STRUCTURES | MERCK PATENT GMBH (DE) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048207-A1 | COMPOUNDS WITH ARYLAMINE STRUCTURES | DDT, NAT1, INMT | MEN1 2014/4885KMT2A 242/4885ATM 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.